In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, for a conversation about quality management. Specifically, they discuss:

• The benefit of investing in quality management for patients, staff, and the organization.
• How Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester evolved and grew its quality management program.
• The advantage of holding 5–10-minute huddles each day.
• How the lab leverages education on quality tools and Gemba Walks to empower all staff to invest in quality management.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories.

They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends. Their conversation covers:

• What’s driving a renewed interest in investing in diagnostics.
• Why the knowledge pathologists have is so valuable in the current landscape.
• How the evolving expectations of laboratory professionals will make it important to stay informed about business trends.

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

Speaker 3: (00:32)
Would you mind telling us a little bit about yourself and your background?

Speaker 3: (01:58)
Would you give us an overview of membranous nephropathy?

Speaker 3: (07:14)
Could you tell us a little bit about this new assay?

Speaker 3: (14:29)
Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?